{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-25-000004","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2025-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.632884+00:00","generated_at":"2026-05-26T23:19:18.992054+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Travere plans sNDA for FILSPARI in FSGS after FDA Type C meeting","bullets":["Completed Type C meeting with FDA; sNDA seeking traditional approval for FILSPARI in FSGS expected by end of Q1 2025.","sNDA will rely on existing Phase 3 DUPLEX and Phase 2 DUET study data for FILSPARI.","PARASOL workgroup findings show proteinuria reduction over 24 months strongly linked to lower kidney failure risk in FSGS.","If approved, FILSPARI could become first and only approved therapy indicated for FSGS, a rare kidney disorder."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-25-000004","json":"https://secwatch.observer/filing/0001438533-25-000004.json","markdown":"https://secwatch.observer/filing/0001438533-25-000004.md","text":"https://secwatch.observer/filing/0001438533-25-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853325000004/0001438533-25-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853325000004/tvtx-20250211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:19:18.992054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}